COLL Q3 2019 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$73M+3.9% YoY

Gross Profit

$26M35.9% margin

Operating Income

-$6M-8.7% margin

Net Income

-$6M-8.4% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-2.8%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$304M

Total Liabilities

$220M

Stockholders' Equity

$84M

Cash & Equivalents

$154M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$70M	+3.9%
Gross Profit	$26M	$24M	+8.4%
Operating Income	-$6M	-$11M	+43.0%
Net Income	-$6M	-$17M	+63.0%

Revenue Segments

Nucynta

$46M64%

Xtampza

$26M36%